Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.
Angelica Fasolo, Luca Gianni(Fondazione Michelangelo), Gianluca Del Conte(IRCCS Ospedale San Raffaele), D. Hess, D. Gibson, Rodrigo Ruiz-Soto, C. Sessa(Vita-Salute San Raffaele University), Giuseppe Capri, J Bauer, Luca Viganò(Humanitas University)
Cited by 1
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
|Annals of Oncology|2022|382
PD-1 Blockade in Anaplastic Thyroid Carcinoma
|Journal of Clinical Oncology|2020|349
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|288